Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
VIVUS, Inc.
ClinicalTrials.gov Identifier:
NCT00895011
First received: May 5, 2009
Last updated: September 14, 2012
Last verified: September 2012

May 5, 2009
September 14, 2012
April 2009
April 2011   (final data collection date for primary outcome measure)
  • Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse [ Time Frame: Baseline, Week 12 ] [ Designated as safety issue: No ]
    Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 3 "Did your erection last long enough for you to have successful intercourse?"
  • The Change in Percentage of Sexual Attempts in Which Subjects Are Able to Insert the Penis Into the Partner's Vagina [ Time Frame: Baseline, Week 12 ] [ Designated as safety issue: No ]
    Data presented as mean change from baseline in the percentage of Yes responses to Sexual Encounter Profile (SEP) diary question 2 "Were you able to insert your penis into your partner's vagina?"
  • Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score [ Time Frame: Baseline, End of Treatment (up to 12 weeks) ] [ Designated as safety issue: No ]
    Questionnaire assesses subject's evaluation of erectile function over the previous 4-week period. Total scores from questions 1-5 & 15 range from 1 to 30. A higher score indicates better erectile function.
  • The change in percent of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • The change in percent of sexual attempts in which subjects are able to insert the penis into the partner's vagina [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
  • The change in score on the erectile function domain of the IIEF questionnaire [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00895011 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy

The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Erectile Dysfunction
  • Drug: Placebo
    One dose 30 minutes prior to initiation of sexual activity
  • Drug: Avanafil
    One dose 30 minutes prior to initiation of sexual activity
    Other Names:
    • TA-1790
    • Stendra
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: Avanafil 100 mg
    Intervention: Drug: Avanafil
  • Experimental: Avanafil 200 mg
    Intervention: Drug: Avanafil
Mulhall JP, Burnett AL, Wang R, McVary KT, Moul JW, Bowden CH, DiDonato K, Shih W, Day WW. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol. 2013 Jun;189(6):2229-36. doi: 10.1016/j.juro.2012.11.177. Epub 2012 Dec 3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
298
April 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult males ≥ 18 years and ≤ 70 years;
  • Have a history of erectile dysfunction of at least 6 months duration following bilateral nerve-sparing retropubic radical prostatectomy;
  • Have a PSA level consistent with the absence of prostate cancer;
  • Have a history of sexual potency prior to radical prostatectomy without requiring medical therapy;
  • Be in a monogamous, heterosexual relationship with their current partner for at least 3 months;
  • Provide written informed consent;
  • Agree to make at least 4 attempts at intercourse per month;
  • Agree not to use any other treatments for erectile dysfunction;
  • Be willing and able to comply with all study requirements (including scheduled study visits, treatment plans, laboratory tests and other study procedures).

Exclusion Criteria

  • Allergy or hypersensitivity to PDE5 inhibitors or any of the components of these drug products;
  • History of dose-limiting AEs during prior treatment with a PDE5 inhibitor or discontinued use of a PDE5 inhibitor due to lack of efficacy at the highest tolerated dose;
  • Concomitant use of one or more of the following medications:

    • Any nitrate, trazodone, itraconazole, ketoconazole, erythromycin, or cimetidine;
    • Other prescription or OTC drugs that are known to interfere with metabolism by the CYP 3A4 enzyme;
    • If receiving hormone replacement therapy (including thyroid supplementation), dose that has not been stable for at least 3 months;
    • If treated with an alpha blocker, dose that has not been stable for at least 14 days;
  • Erectile dysfunction as a consequence of advanced neurologic disease, spinal cord injury, or diabetes;
  • History of severe erectile dysfunction requiring medical therapy prior to bilateral nerve-sparing radical prostatectomy;
  • History of previous pelvic surgery, brachytherapy, or cryotherapy of the prostate;
  • Sexual partner who is under 18 years of age, pregnant, intends to become pregnant during the course of the study, is breastfeeding, has dyspareunia or other gynecologic conditions or other major medical conditions that would interfere with sexual activity or would have difficulty complying with study requirements;
  • Uncontrolled hypertension;
  • Hypotension;
  • Orthostatic hypotension;
  • Myocardial infarction, stroke, life-threatening arrhythmia or coronary revascularization within the past 6 months;
  • Unstable angina, angina with sexual intercourse, or congestive heart failure > NYHA Class II;
  • History or ECG evidence of any high-risk arrhythmia or clinically significant ECG;
  • Hypertrophic, obstructive, or other clinically significant cardiomyopathy, moderate or severe cardiac valvular disease;
  • Type 1 or type 2 diabetes, history of use of any antidiabetic medication;
  • Clinically evident penile lesions, abrasions, anatomical deformities such as penile fibrosis, Peyronie's disease, penile implants, urinary tract or bladder infection, or sexually transmissible disease that the investigator deems to be clinically significant;
  • Condition(s) predisposing to priapism, such as sickle cell disease , multiple myeloma, or leukemia;
  • Any malignancy other than carcinoma of the prostate (except basal cell carcinoma or squamous cell carcinoma of the skin);
  • Prior use of, or likely to require radiotherapy, chemotherapy, androgen deprivation therapy, cryotherapy, non-nerve-sparing surgery, and/or bladder or penile surgery during the study;
  • Evidence of significant hepatic impairment;
  • On dialysis, or history of renal transplantation;
  • Untreated hypogonadism or low serum total testosterone;
  • Abnormal laboratory value(s) judged to be clinically significant by the investigator;
  • Positive STD screen (syphilis, gonorrhea, or chlamydia);
  • Positive for HIV, HCV Ab, or HBsAg at screening;
  • History or current drug, alcohol, or substance abuse;
  • Positive urine drug screen;
  • Positive breath alcohol test;
  • Retinitis pigmentosa or nonarteritic anterior ischemic optic neuropathy;
  • Use of any treatment or device for treatment of erectile dysfunction;
  • Use of any other investigational medication or device for any indication within 30 days prior to enrollment or at any time during this study;
  • Previous participation in any other investigational study of avanafil;
  • Any history of bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity or antidepressant use that has not been stable for at least 3 months;
  • Involvement in the planning and conduct of the study on the part of subject or partner;
  • Evidence of any clinically significant medical, psychiatric, social or other condition by history, physical examination or laboratory studies that, in the opinion of the investigator, would contraindicate the administration of study medications, affect compliance, interfere with study evaluations, limit study participation, contraindicate sexual activity or confound the interpretation of study results.
Male
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00895011
TA-303
No
VIVUS, Inc.
VIVUS, Inc.
Not Provided
Study Director: John Mulhall, MD Memorial Sloan-Kettering Cancer Center
VIVUS, Inc.
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP